^
    3d
    PED-DNX2401: Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, Clinica Universidad de Navarra, Universidad de Navarra | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    tasadenoturev (DNX-2401)
    8d
    PED-DNX2401: Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Clinica Universidad de Navarra, Universidad de Navarra
    Trial initiation date
    |
    tasadenoturev (DNX-2401)
    14d
    PT-112 in Subjects With Thymoma and Thymic Carcinoma (clinicaltrials.gov)
    P2, N=53, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2028 --> Jun 2028
    Trial completion date
    |
    imifoplatin (PT-112)
    19d
    PT-112 in Subjects With Thymoma and Thymic Carcinoma (clinicaltrials.gov)
    P2, N=53, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2027 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    imifoplatin (PT-112)
    25d
    A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients with Recurrent Glioblastoma (ChiCTR2600121471)
    P1, N=27, Completed, Huashan Hospital, Shanghai Medical College, Fudan UniversitynBeijing TianTan Hospital,Capital Medical University; Jecho Biopharmaceuticals Co., Ltd
    New P1 trial
    |
    PVR (PVR Cell Adhesion Molecule)
    25d
    A Single-Arm, Open-Label Phase II Clinical Study to Evaluate the Safety and Efficacy of OVV-01 Injection in Patients with Advanced Soft Tissue Sarcoma (ChiCTR2600120549)
    P=N/A, N=20, Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital
    New trial
    25d
    A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients with Recurrent Glioblastoma (rGBM) (ChiCTR2600119764)
    P1/2, N=90, Huashan Hospital, Shanghai Medical College, Fudan University; nBeijing TianTan Hospital,Capital Medical University; Jecho Biopharmaceuticals Co., Ltd
    New P1/2 trial
    26d
    ARTACUS: Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies (clinicaltrials.gov)
    P1/2, N=69, Active, not recruiting, Replimune, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tudriqev (vusolimogene oderparepvec-wtpg)
    28d
    Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=10, Recruiting, Huashan Hospital
    New P1 trial
    |
    Tecentriq (atezolizumab) • YSCH-01
    1m
    RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis (clinicaltrials.gov)
    P1, N=25, Recruiting, Yana Najjar | Trial completion date: Mar 2027 --> Mar 2029 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    Tudriqev (vusolimogene oderparepvec-wtpg)
    2ms
    A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Jecho Biopharmaceuticals Co., Ltd.
    New P1/2 trial
    2ms
    A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=17, Completed, Jecho Biopharmaceuticals Co., Ltd.
    New P1 trial
    |
    PVR (PVR Cell Adhesion Molecule)